Co reports Q2 loss of 1 cent/share vs analysts' average loss estimate of 2 cents/share.
Co sells and markets FDA-approved prescription medicines for the treatment of various skin conditions.
Up to last close, stock down 16.6% YTD.
Shares rise after revenue beats estimates
Shares of pharmaceutical company Journey Medical DERM.O rise 6.7% to $6.86 premarket.
Co's Q2 revenue of $18.5 million beats analysts' average expectation of $18.4 million, according to data compiled by LSEG.
B. Riley analysts say the results strongly support DERM's investment thesis that growth would come from improving volume and average selling price of its products.
DERM•
